Pharmacological primary and secondary cardiovascular prevention among diabetic patients in a multiethnic general practice population: still room for improvements

Table 1 Characteristics of 1653 patients with type 2 diabetes receiving pharmacological prevention of CVD by ethnicity

Characteristics^a	Valid cases	Norwegians	South Asians	Others^b	P^c
Primary prevention of CVD (n, %)	1273 (100.0)	830 (65.2)	265 (20.8)	178 (14.0)
Males, %	601	47.2	55.7	49.4	0.737
Age, years, mean ( 95% CI)	1273	64.3 (63.4-65.2)	51.0 (49.9-52.1)	54.2 (52.6-55.7)	<0.001
Age at diagnosis of diabetes, years, mean (95% CI)	1180	58.0 (57.1-58.9)	44.6 (43.4-45.7)	48.2 (46.4-50.0)	<0.001
Diabetes duration, years, mean (95% CI)	1180	6.2 (5.8-6.6)	6.1 (5.4-6.8)	5.1 (4.4-5.8)	0.077
Current smoker, % (95% CI)	742	25.7 (22.6-28.9)	10.8 (8.7-13.2)	21.9 (19.0-25.0)	0.001
Secondary prevention of CVD (n, %)	380 (100.0)	299 (78.7)	57 (15.0)	24 (6.3)
Males, %	227	57.5	68.4	66.7	0.238
Age, years, mean, (95% CI)	380	72.4 (71.2-73.6)	58.2 (55.8-60.6)	65.5 (61.2-69.9)	<0.001
Age at diagnosis of diabetes, years, mean, (95% CI)	346	64.7 (63.3-66.0)	46.5 (43.8-49.3)	54.7 (50.1-59.3)	<0.001
Diabetes duration, years, mean (95% CI)	346	7.5 (6.7-8.2)	11.5 (9.4-13.5)	9.5 (7.0-11.9)	0.001
Current smoker, % (95% CI)	240	22.4 (17.7-28.2)	12.1 (8.5-16.7)	20.5 (15.8-26.0)	0.405

^a CVD: cardiovascular disease (i.e. angina pectoris or myocardial infarction or stroke or intermittent claudication).
^b Patients from other regions.
^c p-values. Chi-square test was applied to compare proportion between ethnic groups. One-way ANOVAs were applied to compare mean age, age at diagnosis of diabetes and diabetes duration between ethnic groups.

ISSN: 1472-6963